期刊文献+

螺内酯对扩张型心肌病心力衰竭患者某些体液因子的影响 被引量:4

The effect of spironolactone on some neurohormonal factors in patients suffering cardiac insufficiency secon-dary to dilated cardiomyopathy
下载PDF
导出
摘要 目的 :探讨螺内酯对扩张型心肌病心力衰竭患者血浆儿茶酚胺、肾素活性、血管紧张素Ⅱ及醛固酮的影响。方法 :入选 2 0例扩张型心肌病心力衰竭患者 ,随机分入螺内酯组与对照组 ,各 10例 ,用螺内酯治疗前与治疗 1个月后 ,用高效液相色谱方法测定血浆去甲肾上腺素、肾上腺素 ,同时采用均相竞争放射免疫方法检测血浆肾素活性、血管紧张素 Ⅱ与醛固酮。结果 :治疗 1个月后螺内酯组血浆去甲肾上腺素、肾上腺素、肾素活性及醛固酮明显低于治疗前 ,也低于对照组。结论 :螺内酯可明显抑制扩张型心肌病心力衰竭患者的儿茶酚胺水平 ,降低肾素活性及醛固酮 。 Objective:To determine the effects of spironolactone on neurohormonal factors,catecholamine,plasma renin activity,angiotensin Ⅱ and aldosterone in patients with cardiac insufficiency secondary to dilated cardiomyopathy.Method:Twenty cases suffering cardiac insufficiency secondary to dilated cardiomyopathy were selected and randomly enrolled into two groups,spironolactone group and control group,10 cases in each group.High\|pressure liquid chromatograph(HPLC)was used to detect plasma norepinephrine and adrenaline,plasma renin activity,angiotensin Ⅱ and aldosterone were also analysed by RIAs.Result:Plasma norepinephrine,adrenaline,plasma renin activity and aldosterone in spironolactone group after 1 month treatment were significantly lower than that of the same group before spironolactone treatment and that of control group after 1 month routine therapy.Conclusion:Spironolactone can signifcantly decrease plasma norepinephrine,adrenaline,plasma renin activity and aldosterone in dilated cardiomyopathy patients,these changes may be important mechanisms of spironolactone which could improve the prognosis of congestive heart failure. [
出处 《心肺血管病杂志》 CAS 2003年第2期71-72,共2页 Journal of Cardiovascular and Pulmonary Diseases
关键词 螺内酯 扩张型心肌病 心力衰竭 体液因子 影响 血浆 儿茶酚胺 肾素活性 Spironolactone\ Heart failure\ Catecholamines\ Renin activity\ Aldosterone
  • 相关文献

参考文献3

  • 1Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure.Randomized Aldactone Evaluation Study Investigators. N Engl J Med, 1999,341 (10) :709-717.
  • 2Young J, Heart failure: highlights from new consensus guidelines. Cleve Clin J Med, 2000,67 ( 1 ) : 13-16.
  • 3Struthers AD. Aldosterone escape during ACE inhibitor therapy in chronic heart failure. Eur Heart J,1995,16:103-106.

同被引文献41

  • 1董琦,刘坤申,刘红彬,李树仁,韩玉平,张路平,王颖,刘刚,王小平,徐力飞,李秀彩.急性心肌梗死后螺内酯干预对左室重构的影响[J].中华心血管病杂志,2005,33(4):315-319. 被引量:32
  • 2张芙蓉,孙美玲,田路军.螺内酯对慢性充血性心力衰竭患者的疗效观察[J].现代医药卫生,2005,21(11):1382-1382. 被引量:1
  • 3戴闺柱.2005年美国慢性收缩性心力衰竭治疗指南浅析[J].中华心血管病杂志,2005,33(12):1065-1066. 被引量:64
  • 4吕卓人,黄若文,薛小临.2005年高血压领域中的热点问题[J].中国医刊,2006,41(8):5-7. 被引量:16
  • 5Azizi M. Direct renin inhibition: clinical pharmacology. J Mol Med,2008,86:647-654.
  • 6Rella M, Rushworth CA, Guy JL, et al. Structure based pharmacophore design and virtual screening for novel angiotensin converting enzyme-inhibitors. J Chem Inf Model, 2006,46 : 708 -716.
  • 7Huentelman M J, Zubcevic J, KatovichMJ, et al. Cloning and characterization of a secreted form of angiotensin converting enzyme 2. Regu. Pept, 2004, 122:61-67.
  • 8Zhong JC, Huang DY, Yang YM, et al. Up regulation of angiotensin-converting enzyme 2 by alltrans retinoic acid in spontaneously hypertensive rats. Hypertension, 2004, 44 : 907-912.
  • 9Ishiyama Y, Gallagher PE, Averill DB, et al. Upregulation Angiotensin - Converting Enzyme 2 After Myocardial Infarction by Blockade of Angiotensin Ⅱ Receptors. Hypertension, 2004,43 : 970-976.
  • 10Breschi M C, Calderone V, Digiacomo M, et al. NO2Sartans: A new class of pharmacodynamic hybrids as cardiovascular drugs. J Med Chem, 2004,47:5597-5600.

引证文献4

二级引证文献14

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部